Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2154)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 26.04.24 23:20:55 von
neuester Beitrag 26.04.24 23:20:55 von
Beiträge: 22.815
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 100
Gesamt: 1.231.715
Gesamt: 1.231.715
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVAX
3,8085
EUR
+3,58 %
+0,1315 EUR
Letzter Kurs 26.04.24 Tradegate
Neuigkeiten
20.04.24 · Felix Haupt Anzeige |
16.04.24 · Sharedeals |
18.03.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 7,3500 | +43,84 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,110 | -13,44 | |
| 8,2200 | -13,47 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 63.328.069 von E-Jack-cool_at am 14.04.20 21:14:12https://www.fool.com/investing/2020/04/12/3-top-biotech-stoc…
Antwort auf Beitrag Nr.: 63.318.241 von jarek_1 am 14.04.20 09:42:40stell doch mal biite den link für den Artikel ein
Ich bin mal aufgesprungen, mal schauen wo die reise hingeht.
was glaubt ihr wo die Aktie im MAi steht?
3. Novavax
Novavax (NASDAQ:NVAX) is kind of the oddball in this group of biotech stocks to buy in April. Unlike Gilead Sciences and Vertex, Novavax doesn't have any approved products on the market. It doesn't claim a huge cash stockpile. It's not profitable. But Novavax has been the biggest winner of the three so far in 2020 because of two key developments.
The small biotech captured a lot of attention earlier this year with its progress in developing an experimental COVID-19 vaccine. Novavax's preclinical testing of its vaccine was promising. The company plans to begin clinical testing in humans for its COVID-19 vaccine in May.
An even bigger story for Novavax, though, was its announcement last month of results from a late-stage study evaluating experimental flu vaccine NanoFlu. The nanoparticle-based vaccine beat Sanofi's market-leading flu vaccine Fluzone Quadrivalent in a head-to-head comparison.
Assuming NanoFlu wins FDA approval, Novavax could have a potential blockbuster on its hands in the not-too-distant future. With a market cap of less than $800 million despite the big gains so far this year, I think that Novavax's shares still have plenty of room to run.
Novavax (NASDAQ:NVAX) is kind of the oddball in this group of biotech stocks to buy in April. Unlike Gilead Sciences and Vertex, Novavax doesn't have any approved products on the market. It doesn't claim a huge cash stockpile. It's not profitable. But Novavax has been the biggest winner of the three so far in 2020 because of two key developments.
The small biotech captured a lot of attention earlier this year with its progress in developing an experimental COVID-19 vaccine. Novavax's preclinical testing of its vaccine was promising. The company plans to begin clinical testing in humans for its COVID-19 vaccine in May.
An even bigger story for Novavax, though, was its announcement last month of results from a late-stage study evaluating experimental flu vaccine NanoFlu. The nanoparticle-based vaccine beat Sanofi's market-leading flu vaccine Fluzone Quadrivalent in a head-to-head comparison.
Assuming NanoFlu wins FDA approval, Novavax could have a potential blockbuster on its hands in the not-too-distant future. With a market cap of less than $800 million despite the big gains so far this year, I think that Novavax's shares still have plenty of room to run.
Trading Spotlight
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Kopie aus fremden Medien- bitte nachlesen unter 9.5. Nutzungsbedingungen: "wie zitiere ich richtig"
Ein Impfstoff
Antwort auf Beitrag Nr.: 63.217.107 von decuba12 am 02.04.20 17:11:12Ich bin bisher davon ausgegangen, dass ab Herbst einen Stoff zur Verfügung steht.
Dietmar Hopp (cureVac) Hat das gerade im Interview bestätigt
Dietmar Hopp (cureVac) Hat das gerade im Interview bestätigt
Erstaunlich wenig los hier
Der Ausstzer war gut, habe welche günstig bekommen.
PS.: so viele Meinungen hier?/!
PS.: so viele Meinungen hier?/!
Durchsuchen
16.04.24 · Sharedeals · Novavax |
18.03.24 · wallstreetONLINE Redaktion · Guess? |
03.03.24 · wO Chartvergleich · Allianz |
29.02.24 · Sharedeals · Novavax |
28.02.24 · BörsenNEWS.de · Novavax |
28.02.24 · wallstreetONLINE Redaktion · Novavax |
25.02.24 · wO Chartvergleich · ENCAVIS |
23.02.24 · PR Newswire (dt.) · Novavax |
22.02.24 · wallstreetONLINE Redaktion · Novavax |
21.02.24 · wO Chartvergleich · Dow Jones |